BeyondSpring (BYSI) Q2 2026 earnings summary

Executive summary

• Plinabulin, a novel immune modulator for cancer, is advancing in global Phase 3 studies targeting NSCLC and other indications, with updated Phase 2 data showing a 58% two-year overall survival rate in metastatic NSCLC post-ICI therapy and strong rationale for the confirmatory DUBLIN-4 Phase 3 study; no product sales revenue to date.

• Completed a successful Phase 3 study (DUBLIN-3) in NSCLC, showing significant survival benefit and reduced neutropenia; planning a confirmatory Phase 3 (DUBLIN-4).

• SEED Therapeutics, a subsidiary using a targeted protein degradation platform, is being divested in three tranches, with the first closing completed and two more expected in 2026.

• Leadership transition effective July 1, 2026, aligning focus on DUBLIN-4 and long-term value creation.

Financial highlights

• Net loss for Q2 2026 was $5.7M, up from $4.6M in Q2 2025; net loss for the six months ended June 30, 2026 was $12.4M, up from $3.5M year-over-year.

• R&D expenses for Q2 2026 were $1.0M (flat year-over-year); G&A expenses decreased to $0.8M from $0.9M.

• Cash and cash equivalents plus short-term investments totaled $6.5M as of June 30, 2026.

• Accumulated deficit reached $411.4M as of June 30, 2026.

• No revenue from product sales; $0.5M and $1.0M in collaboration revenue from discontinued operations for Q2 and H1 2026, respectively.

Outlook and guidance

• Expects continued operating losses and negative cash flows; substantial additional funding required to support ongoing clinical development and operations.

• DUBLIN-4 Phase 3 study is the lead clinical priority, with preparations underway for regulatory, operational, and financing needs.

• Exploring strategic options including licensing, partnerships, asset sales, and equity or debt financing.

• Anticipates increased expenses as clinical programs advance, especially for Plinabulin.